Cooperation of p27(Kip1) and p18(INK4c) in progestin-mediated cell cycle arrest in T-47D breast cancer cells

Molecular and Cellular Biology

Volumn 20, Issue 7, 2000, Pages 2581-2591

  Swarbrick, Alexander ^a   Lee, Christine S L ^a   Sutherland, Robert L ^a   Musgrove, Elizabeth A ^a,b  

^a ST VINCENT S HOSPITAL   (Australia)

^b GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE; GESTAGEN; PROTEIN P27; STEROID HORMONE; TRANSFORMING GROWTH FACTOR;

ARTICLE; BREAST CANCER; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; GEL FILTRATION; GENE EXPRESSION; GROWTH INHIBITION; HORMONE ACTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BREAST NEOPLASMS; CARRIER PROTEINS; CELL CYCLE; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P18; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; CYCLINS; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; MICROTUBULE-ASSOCIATED PROTEINS; PREGNENEDIONES; PROGESTINS; RECOMBINANT PROTEINS; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 0034059206     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.20.7.2581-2591.2000     Document Type: Article

References (67)

1. INK4d, a specific inhibitor of cyclin D-dependent kinases. Blood 90:126-137.
2. Adams, P. D., W. R. Sellers, S. K. Sharma, A. D. Wu, C. M. Nalin, and W. Kaelin, Jr. 1996. Identification of a cyclin-cdk2 recognition motif present in substrates and p21-like cyclin-dependent kinase inhibitors. Mol. Cell. Biol. 16:6623-6633.
3. Kip1 with cyclin A-Cdk2 and cyclin D2-Cdk4. J. Biol. Chem. 272:25863-25872.
4. Cip1. Mol. Cell. Biol. 16:4673-4682.
5. Kip1 CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J. 18:1571-1583.
6. Clarke, C. L., and R. L. Sutherland. 1990. Progestin regulation of cellular proliferation. Endocrine Rev. 11:266-302.
7. Della Ragione, F., G. L. Russo, A. Oliva, C. Mercurio, S. Mastropietro, V. Della Peitra, and V. Zappia. 1996. Biochemical characterisation of p16INK4a-and p18-containing complexes in human cell lines. J. Biol. Chem. 271:15942-15949.
8. De Luca, A., T. K. Maclachlan, L. Bagella, C. Dean, C. M. Howard, P. Paulo Claudio, A. Baldi, K. Khalili, and A. Giordano. 1997. A unique domain of pRb2/p130 acts as an inhibitor of Cdk2 kinase activity. J. Biol. Chem. 272: 20971-20974.
9. kip1 in BALB/c 3T3 cells. Mol. Biol. Cell 9:2081-2092.
10. Fiddes, R. J., P. W. Janes, G. M. Sanderson, S. P. Sivertsen, R. L. Sutherland, and R. J. Daly. 1995. Heregulin (HRG)-induced mitogenic signaling and cytotoxic activity of a HRG/PE40 ligand toxin in human breast cancer cells. Cell Growth Differ. 6:1567-1577.
11. Kip1 mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. Genes Dev. 12:2899-2911.
12. INK4c and its predominant association with CDK4 and CDK6 during myogenic differentiation. Mol. Biol. Cell 7:1587-1599.
13. Kip1. Mol. Endocrinol. 11:1593-1607.
14. INK4B/MTS2-relate CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev. 8:2939-2952.
15. Guan, K.-L., C. W. Jenkins, Y. Li, C. L. O'Keefe, S. Noh, X. Wu, M. Zariwala, A. G. Matera, and Y. Xiong. 1996. Isolation and characterisation of p19INK4d, a p16-related inhibitor specific to CDK4 and CDK6. Mol. Biol. Cell 7:57-70.
16. Hall, M., S. Bates, and G. Peters. 1995. Evidence for different modes of action of cyclin-dependent kinase inhibitors: p15 and p16 bind to kinases, p21 and p27 bind to cyclins. Oncogene 11:1581-1588.
17. Harlow, E., and D. Lane. 1988. Antibodies: a laboratory manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
18. Harper, J. W., G. R. Adami, N. Wei, K. Keyomarsi, and S. J. Elledge. 1993. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805-816.
19. Harper, J. W., S. J. Elledge, K. Keyomarsi, B. Dynlacht, L.-H. Tsai, P. Zhang, S. Dobrowlski, C. Bai, L. Connell-Crowley, E. Swindell, M. P. Fox, and N. Wei. 1995. Inhibition of cyclin-dependent kinases by p21. Mol. Biol. Cell 6:387-400.
20. Herman, J. G., A. Merlo, L. Mao, R. G. Lapidus, J.-P. J. Issa, N. E. Davidson, D. Sidransky, and S. B. Baylin. 1995. Inactivation of the CDKN2/p16/ MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 55:4525-4530.
21. Hirai, H., M. F. Roussel, J.-Y. Kato, R. A. Ashmun, and C. J. Sherr. 1995. Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol. Cell. Biol. 15:2672-2681.
22. CO human breast cancer cells by progestins: implications for endocrine therapies. Cancer Res. 45: 167-173.
23. INK4a mRNA is a marker of poor prognosis. Clin. Cancer Res., in press.
24. INK4a-mediated growth suppression. Mol. Cell. Biol. 18: 5284-5290.
25. Kato, A., H. Takahashi, Y. Takahashi, and H. Matsushime. 1997. Inactivation of the cyclin-dependent kinase in the rat fibroblast cell line, 3Y1, induced by contact inhibition. J. Biol. Chem. 272:8065-8070.
26. Kip1) of cyclin-dependem kinase 4 activation. Cell 79:487-496.
27. LaBaer, J., M. D. Garrett, L. F. Stevenson, J. M. Slingerland, C. Sandhu, H. S. Chou, A. Fattaey, and E. Harlow. 1997. New functional activities for the p21 family of CDK inhibitors. Genes Dev. 11:847-862.
28. Ladha, M. H., K. Y. Lee, T. M. Upton, M. F. Reed, and M. E. Ewen. 1998. Regulation of exit from quiescence by p27 and cyclin D1-CDK4. Mol. Cell. Biol. 18:6605-6615.
29. Lange, C. A., J. K. Richer, and K. B. Horwitz. 1999. Hypothesis: progesterone primes breast cancer cells for cross-talk with proliferative or antiproliferative signals. Mol. Endocrinol. 13:829-836.
30. Lee, M. H., I. Reynisdottir, and J. Massagué. 1995. Cloning of p57kip2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev. 9:639-649.
31. Mahony, D., D. A. Parry, and E. Lees. 1998. Active cdk6 complexes are predominantly nuclear and represent only a minority of the cdk6 in T cells. Oncogene 16:603-611.
32. Cip1 in mouse macrophages. Oncogene 16:2075-2086.
33. INK4a inhibits both CDK4-and CDK2-associated kinase activity by reassortment of cyclin-CDK-inhibitor complexes. Mol. Cell. Biol. 19:1981-1989.
34. INK4a. Mol. Cell. Biol. 19:3916-3928.
35. Montagnoli, A., F. Fiore, E. Eytan, A. C. Carrano, G. F. Draetta, A. Hershko, and M. Pagano. 1999. Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. Genes Dev. 13:1181-1189.
36. Morgan, D. O. 1995. Principles of CDK regulation. Nature 374:131-134.
37. Morse, L., D. Chen, D. Franklin, Y. Xiong, and S. Chen-Kiang. 1997. Induction of cell cycle arrest and B cell terminal differentiation by CDK inhibitor p18(INK4c) and IL-6. Immunity 6:47-56.
38. Müller, D., C. Bouchard, B. Rudolph, P. Steiner, I. Stuckmann, R. Saffrich, W. Ansorge, W. Huttner, and M. Eilers. 1997. Cdk2-dependent phosphorylation of p27 facilitates its Myc-induced release from cyclin E/cdk2 complexes. Oncogene 15:2561-2576.
39. Musgrove, E. A., J. A. Hamilton, C. S. L. Lee, K. J. E. Sweeney, C. K. W. Watts, and R. L. Sutherland. 1993. Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol. Cell. Biol. 13:3577-3587.
40. Musgrove, E. A., C. S. L. Lee, and R. L. Sutherland. 1991. Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor α, epidermal growth factor receptor, c-fos; and c-myc genes. Mol. Cell. Biol. 11:5032-5043.
41. Musgrove, E. A., A. Swarbrick, C. S. L. Lee, A. L. Cornish, and R. L. Sutherland. 1998. Mechanisms of CDK inactivation by progestins. Mol. Cell. Biol. 18:1812-1825.
42. h: a GTP-binding protein with transglutaminase activity and receptor signaling function. Science 264:1593-1596.
43. 1 cyclin-dependent kinase inhibitor, is dependent on CDK2 activity and the proteosome. Mol. Cell. Biol. 19:1190-1201.
44. Parry, D., D. Mahony, K. Wills, and E. Lees. 1999. Cyclin D-CDK subunit arrangement is dependent on the availability of competing INK4 and p21 class inhibitors. Mol. Cell. Biol. 19:1775-1783.
45. Kip1. Cell Growth Differ. 9:595-610.
46. Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev. 8:9-22.
47. Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78:59-66.
48. 1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. J. Biol. Chem. 272:10882-10894.
49. Kip1 coordinate their inhibitory interactions with cdk4 and cdk2. Genes Dev. 11:492-503.
50. Reynisdóttir, I., K. Polyak, A. Iavarone, and J. Massagué. 1995 Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-β. Genes Dev. 9:1831-1845.
51. Sarcevic, B., R. Lilischkis, and R. L. Sutherland. 1997. Differential phosphorylation of T-47D human breast cancer cell substrates by D1-, D3-, E-, and A-cyclin-CDK complexes. J. Biol. Chem. 272:33327-33337.
52. Sheaff, R. J., M. Groudine, M. Gordon, J. M. Roberts, and B. E. Clurman. 1997. Cyclin E-CDK2 is a regulator of p27kip1. Genes Dev. 11:1464-1478.
53. Sherr, C. J. 1996. Cancer cell cycles. Science 274:1672-1677.
54. 1-phase progression. Genes Dev. 13:1501-1512.
55. Kip1 in growth inhibition of endometrium in the secretory phase and of hyperplastic endometrium treated with progesterone. Mol. Hum. Reprod. 4:899-905.
56. Shirane, M., Y. Harumiya, I. Noriko, A. Hirai, C. Miyamoto, S. Hatakeyama, K. Nakayama, and M. Kitagawa. 1999. Down-regulation of p27kip1 by two mechanisms, ubiquitin-mediated degradation and proteolytic processing. J. Biol. Chem. 274:13886-13893.
57. Singh, S. P., J. Lipman, H. Goldman, F. H. Ellis, Jr., L. Aizenman, M. G. Cangi, S. Signoretti, D. S. Chiaur, M. Pagano, and M. Loda. 1998. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res. 58:1730-1735.
58. Soos, T. J., H. Kiyokawa, J. S. Yan, M. S. Rubin, A. Giordano, A. DeBlasio, S. Bottega, B. Wong, J. Mendelsohn, and A. Koff. 1996. Formation of p27-CDK complexes during the human mitotic cell cycle. Cell Growth Differ, 7:135-146.
59. 1 cyclin expression in breast cancer cells. Oncogene 16:2865-2878.
60. Kip1, an inhibitor of G1 cyclin-dependent kinases, uncouples differentiation and growth arrest during the granulosa-luteal transition. Cell Growth Differ. 9:787-794.
61. Tong, W., and J. W. Pollard. 1999. Progesterone inhibits estrogen-induced cyclin D1 and cdk4 nuclear translocation, cyclin E-and cyclin A-cdk2 kinase activation, and cell proliferation in uterine epithelial cells in mice. Mol. Cell. Biol. 19:2251-2264.
62. Toyoshima, H., and T. Hunter. 1994. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 78:67-74.
63. Veronesi, U., A. Goldhirsch, and J. Yarnold. 1995. Breast cancer, p. 1243-1289. In M. Peckham, H. M. Pinedo, and U. Veronesi (ed.), Oxford textbook of oncology. Oxford University Press, Oxford, England.
64. Vignon, F., S. Bardon, D. Chalbos, and H. Rochefort. 1983. Antiestrogenic effect of R5020, a synthetic progestin in human breast cancer cells in culture. J. Clin. Endocrinol. Metab. 56:1124-1130.
65. Kip1 is abrogated by c-Myc. EMBO J. 15:6595-6604.
66. 1 arrest pathway. Mol. Cell. Biol. 19:5913-5922.
67. Weinberg, R. A. 1995. The retinoblastoma protein and cell cycle control. Cell 81:323-330.